Erdafitinib

Drug Profile

Erdafitinib

Alternative Names: G-024; JNJ-42756493; JNJ-493

Latest Information Update: 18 Jul 2017

Price : $50

At a glance

  • Originator Astex Therapeutics
  • Developer Janssen Research & Development
  • Class Antineoplastics; Diamines; Pyrazoles; Quinoxalines; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Urogenital cancer
  • Phase I/II Hepatocellular carcinoma; Lymphoma; Solid tumours
  • Phase I Cancer
  • Preclinical Multiple myeloma

Most Recent Events

  • 06 Jul 2017 National Cancer Institute plans a phase II Pediatric MATCH trial for Solid tumours and Non-Hodgkin lymphoma (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT03210714)
  • 03 Jun 2017 Safety and efficacy data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 12 May 2017 Janssen Research & Development and Celerion completes a phase I trial in Healthy volunteers in USA (PO) (NCT03066687)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top